Show simple item record

dc.contributor.authorGonzález López, Tomás José
dc.contributor.authorSánchez González, Blanca
dc.contributor.authorJarque, Isidro
dc.contributor.authorBernat, Silvia
dc.contributor.authorFernández Fuertes, Fernando
dc.contributor.authorCaparrós, Isabel
dc.contributor.authorSoto, Inmaculada
dc.contributor.authorFernández Rodríguez, Angeles
dc.contributor.authorBolaños, Estefanía
dc.contributor.authorPérez Rus, Gloria
dc.contributor.authorPascual, Cristina
dc.contributor.authorHernández Rivas, José Angel
dc.contributor.authorLópez Ansoar, Elsa
dc.contributor.authorGómez Nuñez, Marta
dc.contributor.authorMartínez Robles, Violeta
dc.contributor.authorOlivera, Pavel
dc.contributor.authorYera Cobo, Maria
dc.contributor.authorPeñarrubia, María Jesús
dc.contributor.authorFernández Miñano, Carmen
dc.contributor.authorCabo, Erik
dc.contributor.authorMartínez Badas, María Paz
dc.contributor.authorPerdomo Hernández, Germán M. 
dc.contributor.authorGarcía Frade, Luis Javier
dc.date.accessioned2020-03-13T11:04:12Z
dc.date.available2020-03-13T11:04:12Z
dc.date.issued2020-03
dc.identifier.issn0902-4441
dc.identifier.urihttp://hdl.handle.net/10259/5243
dc.description.abstractBackground Eltrombopag is useful for immune thrombocytopenia (ITP). However, results of clinical trials may not accurately mirror clinical practice reality. Here we evaluated eltrombopag for primary and secondary ITP in our ≥65‐year‐old population. Methods A total of 106 primary ITP patients (16 with newly diagnosed ITP, 16 with persistent ITP, and 74 with chronic ITP) and 39 secondary ITP patients (20 with ITP secondary to immune disorders, 7 with ITP secondary to infectious diseases, and 12 with ITP secondary to lymphoproliferative disorders [LPD]) were retrospectively evaluated. Results Median age of our cohort was 76 (interquartile range, IQR, 70‐81) years. 75.9% of patients yielded a platelet response including 66.2% complete responders. Median time to platelet response was 14 (IQR, 8‐21) days. Median time on response was 320 (IQR, 147‐526) days. Sixty‐three adverse events (AEs), mainly grade 1‐2, occurred. The most common were hepatobiliary laboratory abnormalities (HBLAs) and headaches. One transient ischemic attack in a newly diagnosed ITP and two self‐limited pulmonary embolisms in secondary ITP were the only thrombotic events observed. Conclusion Eltrombopag showed efficacy and safety in ITP patients aged ≥65 years with primary and secondary ITP. However, efficacy results in LPD‐ITP were poor. A relatively high number of deaths were observed.en
dc.format.mimetypeapplication/pdf
dc.language.isoenges
dc.publisherJohn Wiley & Sonses
dc.relation.ispartofEuropean Journal of Haematology. 2020, V. 104, n. 3, p. 259-270es
dc.subjectelderlyen
dc.subjecteltrombopagen
dc.subjectimmune thrombocytopeniaen
dc.subjectprimaryen
dc.subjectsecondaryen
dc.subject.otherSistema cardiovascular-Enfermedadeses
dc.subject.otherCardiovascular system-Diseasesen
dc.titleUse of eltrombopag for patients 65 years old or older with immune thrombocytopeniaen
dc.typeinfo:eu-repo/semantics/article
dc.rights.accessRightsinfo:eu-repo/semantics/embargoedAccess
dc.relation.publisherversionhttps://doi.org/10.1111/ejh.13370
dc.identifier.doi10.1111/ejh.13370
dc.identifier.essn1600-0609
dc.journal.titleEuropean Journal of Haematologyes
dc.volume.number104es
dc.issue.number3es
dc.page.initial259es
dc.page.final270es
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion


Files in this item

This item appears in the following Collection(s)

Show simple item record